Análisis crítico del tratamiento de la enfermedad hepática grasa no alcohólica

Código QR

Análisis crítico del tratamiento de la enfermedad hepática grasa no alcohólica

Non-alcoholic fatty liver disease (NAFDL) includes fatty liver or simple steatosis, characterized by lipid deposits in hepatocytes and more advanced stages such as steatohepatitis (NASH) and non-alcoholic cirrhosis. Physical inactivity, hypercaloric and unbalanced diet together with aging play a key...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lanuza,Fabian, Sapunar,Jorge, Hofmann,Edmundo
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2018
Materias:	Non-alcoholic Fatty Liver Disease Diet Exercise Pharmacology
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872018000800894
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Cuantificación de esteatosis hepática no alcohólica por resonancia magnética
por: Herrera,Rodrigo, et al.
Publicado: (2019)

Rol de la microbiota intestinal en el desarrollo del hígado graso no alcohólico
por: Tumani,María Fernanda, et al.
Publicado: (2021)

Alteraciones de la tolerancia a la glucosa y frecuencia de síndrome metabólico en pacientes con enfermedad por hígado graso no alcohólico
por: Araya Q,A. Verónica, et al.
Publicado: (2006)

The negative and detrimental effects of high fructose on the liver, with special reference to metabolic disorders
por: Mai BH, et al.
Publicado: (2019)

Foresight regarding drug candidates acting on the succinate–GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment
por: Chengyuan Liang, et al.
Publicado: (2021)

Non-Alcoholic Fatty Liver Disease as a Risk for Colorectal Cancer Development and the Role of Screening Colonoscopy in Clinical Practice
por: Cosmas Rinaldi Adithya Lesmana, et al.
Publicado: (2019)

Non-Alcoholic Fatty Liver Disease and Hypothyroidism: Review of Clinical and Experimental Studies
por: Tetiana Ranhulova
Publicado: (2021)

Effects of DHA dietary intervention on hepatic lipid metabolism in apolipoprotein E-deficient and C57BL/6J wild-type mice
por: Jingjing Xu, et al.
Publicado: (2021)

Body Mass Index and Indicators of Lipid Exchange in Liver Steatosis of Alcoholic and Nonalcoholic Genesis in Residents of Rural Area: Similarities and Differences
por: N. V. Mikhaylova, et al.
Publicado: (2019)

NON-ALCOHOLIC STEATOHEPATITIS IN CHILDREN − A PRACTICAL APPROACH WITH CASE REPORT
por: Ana Šinkovec, et al.
Publicado: (2021)

Effect of Long-Term Exercise on Liver Lipid Metabolism in Chinese Patients With NAFLD: A Systematic Review and Meta-Analysis
por: Ye Gao, et al.
Publicado: (2021)

DHA Protects Against Hepatic Steatosis by Activating Sirt1 in a High Fat Diet-Induced Nonalcoholic Fatty Liver Disease Mouse Model
por: Luo X, et al.
Publicado: (2020)

Non-invasive Diagnostics of Liver Fibrosis
por: Mihaylov R., et al.
Publicado: (2017)

Diagnostic significance of clinical and laboratory indices in predicting non-alcoholic fatty liver disease during screening studies
por: Aleksandr E. Nosov, et al.
Publicado: (2021)

Cytoprotective and suicidal signaling in oxidative stress
por: Videla,Luis A
Publicado: (2010)

Association of Cholecystectomy With Liver Fibrosis and Cirrhosis Among Adults in the USA: A Population-Based Propensity Score-Matched Study
por: Zhi-Qin Xie, et al.
Publicado: (2021)

Blancos terapéuticos potenciales para revertir la cirrosis hepática
por: García B,Leonel, et al.
Publicado: (2007)

Diagnostics and treatment of non-alcoholic fatty liver disease with concomitant asthenic syndrome
por: Aleksandr I. Pavlov, et al.
Publicado: (2021)

Obesity and nonalcoholic fatty liver disease: current perspectives
por: Sarwar R, et al.
Publicado: (2018)

What Do We Know about Inequalities in NAFLD Distribution and Outcomes? A Scoping Review
por: Mar Talens, et al.
Publicado: (2021)

Inadequate identification of fatty liver disease, obesity, and metabolic syndrome by family physicians
por: Mahamid M, et al.
Publicado: (2018)

Impact of <i>Helicobacter pylori</i>-Related Metabolic Syndrome Parameters on Arterial Hypertension
por: Jannis Kountouras, et al.
Publicado: (2021)

Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C
por: Pegah Golabi, et al.
Publicado: (2022)

Accumulation of Genetic and Epigenetic Alterations in the Background Liver and Emergence of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease
por: Satoru Hagiwara, et al.
Publicado: (2021)

The Contribution of Dietary Fructose to Non-alcoholic Fatty Liver Disease
por: Siyu Yu, et al.
Publicado: (2021)

Adiponutrin and Adiponectin Gene Variants in Indonesian Patients with Non-Alcoholic Fatty Liver Disease: a Preliminary Study
por: Rayvita AN Meagratia, et al.
Publicado: (2021)

Editorial: New Insights Into Understanding and Managing NAFLD
por: Óscar Escribano, et al.
Publicado: (2021)

Saroglitazar and Hepano treatment offers protection against high fat high fructose diet induced obesity, insulin resistance and steatosis by modulating various class of hepatic and circulating lipids
por: Soumalya Sarkar, et al.
Publicado: (2021)

Activation and Functional Priming of Blood Neutrophils in Non-Alcoholic Fatty Liver Disease Increases in Non-Alcoholic Steatohepatitis
por: Lauszus JS, et al.
Publicado: (2021)

(+)-Dehydrovomifoliol Alleviates Oleic Acid-Induced Lipid Accumulation in HepG2 Cells via the PPARα–FGF21 Pathway
por: Yiyuan Xi, et al.
Publicado: (2021)

Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets
por: Daniela Maria Tanase, et al.
Publicado: (2021)

Effect of tele-nursing in the improving of the ultrasound findings in patients with nonalcoholic fatty liver diseases: A Randomized Clinical Trial study
por: Fariba Ghodsbin, et al.
Publicado: (2018)

Ethnic differences and heterogeneity in genetic and metabolic makeup contributing to nonalcoholic fatty liver disease
por: Szanto KB, et al.
Publicado: (2019)

Clinical and Metabolic Characteristics of Non-Alcoholic Fatty Liver Disease Patients in Saudi Arabia: Data from the Systematic Observatory Liver Disease (SOLID) Registry
por: Alswat K, et al.
Publicado: (2021)

Reduced Rank Regression-Derived Dietary Patterns Related to the Fatty Liver Index and Associations with Type 2 Diabetes Mellitus among Ghanaian Populations under Transition: The RODAM Study
por: Tracy Bonsu Osei, et al.
Publicado: (2021)

Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data
por: Diaz Soto MP, et al.
Publicado: (2020)

Ginkgo biloba Extract 50 (GBE50) Ameliorates Insulin Resistance, Hepatic Steatosis and Liver Injury in High Fat Diet-Fed Mice
por: Li L, et al.
Publicado: (2021)

Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial
por: Fatemeh Naeini, et al.
Publicado: (2021)

Current concepts of the pathogenesis of non-alcoholic fatty liver disease
por: Evgenia Pavlovna Kosobyan, et al.
Publicado: (2010)

High-Normal Serum Thyrotropin Levels Increased the Risk of Non-Alcoholic Fatty Liver Disease in Euthyroid Subjects with Type 2 Diabetes
por: Tan Y, et al.
Publicado: (2021)